You are here:

abatacept (Orencia)

Advice

in the absence of a submission from the holder of the marketing authorisation:

abatacept (Orencia®) is not recommended for use within NHS Scotland.

Indication under review: Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: abatacept (Orencia)
SMC Drug ID: 1287/17
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 November 2017

Back